HeN) and transgenic P301S and Tg2576 mice - PubMed (original) (raw)

doi: 10.1002/psc.2518. Epub 2013 Jun 3.

Affiliations

PMID: 23728915
DOI: 10.1002/psc.2518

T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice

Monique Richter et al. J Pept Sci. 2013 Jul.

Abstract

Alzheimer's disease is characterized by two pathological hallmarks, the intracellular deposition of hyperphosphorylated Tau protein and the extracellular deposition of Aβ1-40/42 , both being targets for immunotherapy. This study evaluates the immunogenic properties of three AD-specific B-cell epitopes (Tau229-237 [pT231/pS235], pyroGluAβ3-8 , and Aβ37/38-42/43 ) linked to five foreign T-cell epitopes (MVFP, TT, TBC Ag85B, PvT19, and PvT53) by immunizing inbred C57BL/6J (H-2(b) ), SJL/J (H-2(s2) ), and C3H/HeN (H-2(k) ) mice. Two promising candidates with respect to MHC II restriction were selected, and two transgenic mouse models of AD, P301S (H-2(b/) (k) ) and Tg2576 (H-2(b/) (s) ) animals, were immunized with one B-cell epitope in combination with two T-cell epitopes. Responders displayed an enhanced immune response compared with wild-type animals, which supports the vaccine design and the vaccination strategy. The immune response was also characterized by specific IgG subtype titers, which revealed a strong polarization toward the humoral pathway for immunization of phospho-Tau, whereas for both Aβ vaccines, a mixed cellular/humoral pathway response was observed. Despite the diversity and unpredictability of the immunogenicity of the peptide vaccines, all three peptide vaccine formulations appear to be promising constructs for future evaluation of their therapeutic properties.

PubMed Disclaimer

Cited by

A walk through tau therapeutic strategies.
Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N. Jadhav S, et al. Acta Neuropathol Commun. 2019 Feb 15;7(1):22. doi: 10.1186/s40478-019-0664-z. Acta Neuropathol Commun. 2019. PMID: 30767766 Free PMC article. Review.
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.
Richter M, Mewes A, Fritsch M, Krügel U, Hoffmann R, Singer D. Richter M, et al. Vaccines (Basel). 2014 Jul 29;2(3):601-23. doi: 10.3390/vaccines2030601. Vaccines (Basel). 2014. PMID: 26344748 Free PMC article.
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. Kontsekova E, et al. Alzheimers Res Ther. 2014 Aug 1;6(4):44. doi: 10.1186/alzrt278. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25478017 Free PMC article.
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.
Kontsekova E, Zilka N, Kovacech B, Skrabana R, Novak M. Kontsekova E, et al. Alzheimers Res Ther. 2014 Aug 1;6(4):45. doi: 10.1186/alzrt277. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25478018 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Molecular Biology Databases
- Immune Epitope Database and Analysis Resource
Research Materials
- NCI CPTC Antibody Characterization Program

T-cell epitope-dependent immune response in inbred (C57BL/6J, SJL/J, and C3H/HeN) and transgenic P301S and Tg2576 mice - PubMed (original) (raw)